Discussion
hyperkalemia
To our knowledge, the KBindER trial is the first to evaluate the efficacy of SPS, patiromer and sodium zirconium cyclosilicate head-to-head in ER and hospitalized patients with acute hyperkalemia. The results will be highly relevant to patient outcomes and healthcare spending; patients who are admitted to the hospital with hyperkalemia spend on average 4 additional days in the hospital compared to matched, non-hyperkalemic inpatients and incur USD $15,606 higher in total health care costs over a one year period [Based on available data (Table It is timely to re-evaluate the utility of SPS in the treatment of acute hyperkalemia. If SPS proves to have equivalent or lower efficacy in lowering KOur study is not intended to identify superiority of one oral KIn summary, the KBindER trial is the first head-to-head evaluation of oral potassium binders in a real-world setting where temporizing therapies will be given per discretion of the medical team. The findings from our study will inform decision-making guidelines for the treatment of acute hyperkalemia.